指南与共识胸部技术与安全CTDR

抗癌药物诱导间质性肺病诊治专家共识

Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease.
指南 / 共识 · Curr Med Sci · 2023-03-03

抗癌药物诱导间质性肺病(DILD)是最常见的肺部不良事件,随着新型抗癌药快速发展其发病率逐渐升高。由于临床表现多样且缺乏特异性诊断标准,DILD诊断困难,处理不当可能致命。中国肿瘤、呼吸、影像、药理、病理及放射等多学科专家组经多轮全面调研达成此专家共识,旨在提高临床医生认识,为DILD的早期筛查、诊断和治疗提供推荐意见,并强调多学科协作管理DILD的重要性。

要点

  • 抗癌药物诱导间质性肺病(DILD)是最常见的肺部不良事件,新型抗癌药快速发展使其发病率逐渐升高。
  • DILD临床表现多样且缺乏特异性诊断标准,诊断困难,处理不当可能致命。
  • 本共识由多学科专家组制定,强调DILD管理中多学科协作的重要性。

核心结论

  • 该共识旨在提高临床医生对DILD的认识,并为DILD的早期筛查、诊断和治疗提供推荐意见。
  • 共识强调多学科协作在DILD管理中的重要性。

研究设计与样本

  • 本文件为专家共识,由中国肿瘤、呼吸、影像、药理、病理及放射等多学科专家组经多轮全面调研后达成。
  • 原文未报告共识制定的具体方法学及证据分级。

诊断标准与关键数值

  • 原文未报告具体的诊断标准、敏感度、特异度、AUC或阈值。

临床应用与阅片要点

  • 原文未据此给出具体的阅片或报告推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Drug-induced interstitial lung disease (DILD) is the most common pulmonary adverse event of anticancer drugs. In recent years, the incidence of anticancer DILD has gradually increased with the rapid development of novel anticancer agents. Due to the diverse clinical manifestations and the lack of specific diagnostic criteria, DILD is difficult to diagnose and may even become fatal if not treated properly. Herein, a multidisciplinary group of experts from oncology, respiratory, imaging, pharmacology, pathology, and radiology departments in China has reached the "expert consensus on the diagnosis and treatment of anticancer DILD" after several rounds of a comprehensive investigation. This consensus aims to improve the awareness of clinicians and provide recommendations for the early screening, diagnosis, and treatment of anticancer DILD. This consensus also emphasizes the importance of multidisciplinary collaboration while managing DILD.

来源:Curr Med Sci,查看原文。版权归原作者所有。

引用

  1. Dai, Ma, Ren, et al. Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. Curr Med Sci. 2023. PMID: 36867358. doi:10.1007/s11596-022-2693-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。